Physician profile
Daniel A Brown
NPI 1558474940
$4,239.85
in general payments reported to CMS, 2019-2025
23 companies · $310 in 2025
The $310 reported for 2025 was more than what 87% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $791 · 2020: $351 · 2021: $709 · 2022: $812 · 2023: $872 · 2024: $394 · 2025: $310.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,557 · Education: $19.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,556.95 |
| Education | $19.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,930.96 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $773.37 | 2020-2025 | Entyvio, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $718.04 | 2019-2023 | Xifaxan, Plenvu |
| Janssen Biotech, INC. | $130.00 | 2019-2023 | Stelara, Remicade, Simponi |
| Ferring Pharmaceuticals INC. | $115.07 | 2019-2023 | Rebyota |
| Braintree Laboratories, INC. | $102.99 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $56.61 | 2022-2023 | |
| Redhill Biopharma INC. | $48.46 | 2021-2022 | |
| Qol Medical, LLC | $39.42 | 2022-2023 | Sucraid |
| Daiichi Sankyo INC. | $32.85 | 2019-2020 | |
| Amgen INC. | $32.08 | 2023 | Avsola, Amjevita |
| Merck Sharp & Dohme LLC | $30.74 | 2023 | Dificid |
| Ardelyx, INC. | $29.51 | 2023 | Ibsrela |
| Medline Industries LP | $26.00 | 2025 | |
| Halozyme INC | $25.62 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $23.00 | 2023 | Imfinzi |
| Abbott Laboratories | $21.95 | 2024 | Proclaim |
| Celltrion USA INC. | $19.60 | 2023 | Yuflyma |
| Intercept Pharmaceuticals, INC. | $18.96 | 2023 | Ocaliva |
| Fresenius Kabi USA, LLC | $18.59 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $16.55 | 2023 | Dupixent |
| Ironwood Pharmaceuticals, INC | $15.19 | 2023 | Linzess |
| Lilly USA, LLC | $14.29 | 2025 | Omvoh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.